Literature DB >> 8005387

Cell surface down-modulation of CD4 after infection by HIV-1.

R Geleziunas1, S Bour, M A Wainberg.   

Abstract

Entry of HIV-1 into host cells is generally mediated by the cell surface CD4 receptor after specific interaction with the viral envelope glycoprotein gp120. Infection by HIV-1 commonly leads to the disappearance of CD4 from the plasma membrane, a phenomenon referred to as receptor down-modulation. This, in turn, renders cells refractory to subsequent infection by the same or other viruses that use the CD4 receptor for entry, creating a state of superinfection immunity. CD4 down-modulation is a complex process involving a variety of viral gene products, the effects of which may be manifest at different stages within the viral replication cycle. CD4 disappearance from the cell surface occurs in each of the CD4+ lymphocytes, T-cell lines, monocytic cell lines, and monocyte-derived macrophages. Internalization of CD4 can occur after binding of either gp120 alone or gp120 antigen-antibody complexes, and may also be mediated by the HIV-1 Nef gene. Other factors that cause cell surface CD4 depletion include reductions in CD4 transcript levels, impaired translation of CD4 mRNA, formation of CD4-gp160 intracellular complexes, and degradation of CD4 mediated by the HIV-1 Vpu gene.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8005387     DOI: 10.1096/fasebj.8.9.8005387

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  27 in total

1.  Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses.

Authors:  Daniel A Donahue; Sophie M Bastarache; Richard D Sloan; Mark A Wainberg
Journal:  J Virol       Date:  2013-06-26       Impact factor: 5.103

2.  Contribution of Vpu, Env, and Nef to CD4 down-modulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection.

Authors:  Steffen Wildum; Michael Schindler; Jan Münch; Frank Kirchhoff
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

3.  The role of the LDL receptor in apolipoprotein B secretion.

Authors:  J Twisk; D L Gillian-Daniel; A Tebon; L Wang; P H Barrett; A D Attie
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

4.  Inhibitory effect of interleukin-16 on interleukin-2 production by CD4+ T cells.

Authors:  H Ogasawara; N Takeda-Hirokawa; I Sekigawa; H Hashimoto; Y Kaneko; S Hirose
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

Review 5.  Virological and Immunological Outcomes of Coinfections.

Authors:  Naveen Kumar; Shalini Sharma; Sanjay Barua; Bhupendra N Tripathi; Barry T Rouse
Journal:  Clin Microbiol Rev       Date:  2018-07-05       Impact factor: 26.132

6.  Envelope protein-mediated down-regulation of hepatitis B virus receptor in infected hepatocytes.

Authors:  K M Breiner; S Urban; B Glass; H Schaller
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

7.  Evidences for viral strain selection in late stages of HIV infection: an analysis of Vpu alleles.

Authors:  Marcos Vinícius Pereira Gondim; Joaquim Xavier da Silva; Francisco Prosdocimi; Eduardo Leonardecz-Neto; Octávio Luiz Franco; Enrique Roberto Argañaraz
Journal:  Protein J       Date:  2012-02       Impact factor: 2.371

8.  Binding of HIV-2 envelope glycoprotein to CD8 molecules and related chemokine production.

Authors:  H Akimoto; H Kaneko; I Sekigawa; H Hashimoto; Y Kaneko; N Yamamoto
Journal:  Immunology       Date:  1998-10       Impact factor: 7.397

Review 9.  Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea.

Authors:  J Steinmann; J Buer; T Pietschmann; E Steinmann
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

10.  Nef-induced CD4 endocytosis in human immunodeficiency virus type 1 host cells: role of p56lck kinase.

Authors:  Nadine Laguette; Christelle Brégnard; Jérôme Bouchet; Alexandre Benmerah; Serge Benichou; Stéphane Basmaciogullari
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.